These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Dietary salt intake and time to relapse in paediatric multiple sclerosis. Nourbakhsh B; Graves J; Casper TC; Lulu S; Waldman A; Belman A; Greenberg B; Weinstock-Guttman B; Aaen G; Tillema JM; Hart J; Ness J; Rubin J; Krupp L; Gorman M; Benson L; Rodriguez M; Chitnis T; Rose J; Barcellos L; Waubant E; J Neurol Neurosurg Psychiatry; 2016 Dec; 87(12):1350-1353. PubMed ID: 27343226 [TBL] [Abstract][Full Text] [Related]
45. Disability and prognosis of relapsing remitting multiple sclerosis, is it different in Iraqi patients? Hasan ZN Neurosciences (Riyadh); 2011 Jul; 16(3):233-6. PubMed ID: 21677613 [TBL] [Abstract][Full Text] [Related]
46. Puberty onset and pediatric multiple sclerosis activity in boys. Young B; Waubant E; Lulu S; Graves J Mult Scler Relat Disord; 2019 Jan; 27():184-187. PubMed ID: 30390578 [TBL] [Abstract][Full Text] [Related]
47. Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Spelman T; Gray O; Trojano M; Petersen T; Izquierdo G; Lugaresi A; Hupperts R; Bergamaschi R; Duquette P; Grammond P; Giuliani G; Boz C; Verheul F; Oreja-Guevara C; Barnett M; Grand'Maison F; Edite Rio M; Lechner-Scott J; Van Pesch V; Fernandez Bolanos R; Flechter S; Den Braber-Moerland L; Iuliano G; Amato MP; Slee M; Cristiano E; Saladino ML; Paine M; Vella N; Kasa K; Deri N; Herbert J; Moore F; Petkovska-Boskova T; Alroughani R; Savino A; Shaw C; Vucic S; Santiago V; Bacile EA; Skromne E; Poehlau D; Cabrera-Gomez JA; Lucas R; Butzkueven H Ann Neurol; 2014 Dec; 76(6):880-90. PubMed ID: 25283272 [TBL] [Abstract][Full Text] [Related]
48. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. Kingwell E; van der Kop M; Zhao Y; Shirani A; Zhu F; Oger J; Tremlett H J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):61-6. PubMed ID: 21865212 [TBL] [Abstract][Full Text] [Related]
49. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. Ramtahal J; Jacob A; Das K; Boggild M J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994 [TBL] [Abstract][Full Text] [Related]
50. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898 [TBL] [Abstract][Full Text] [Related]
51. Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Oikonen M; Laaksonen M; Aalto V; Ilonen J; Salonen R; Erälinna JP; Panelius M; Salmi A Mult Scler; 2011 Jun; 17(6):672-80. PubMed ID: 21212088 [TBL] [Abstract][Full Text] [Related]
53. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253 [TBL] [Abstract][Full Text] [Related]
54. Barkhof magnetic resonance imaging criteria predict early relapse in pediatric multiple sclerosis. Neuteboom RF; Ketelslegers IA; Boon M; Catsman-Berrevoets CE; Hintzen RQ; Pediatr Neurol; 2010 Jan; 42(1):53-5. PubMed ID: 20004863 [TBL] [Abstract][Full Text] [Related]
56. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
57. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821 [TBL] [Abstract][Full Text] [Related]
58. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Sormani MP; Rovaris M; Comi G; Filippi M Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123 [TBL] [Abstract][Full Text] [Related]
59. Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study. Pan G; Simpson S; van der Mei I; Charlesworth JC; Lucas R; Ponsonby AL; Zhou Y; Wu F; Taylor BV J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1204-1211. PubMed ID: 27559181 [TBL] [Abstract][Full Text] [Related]
60. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Binquet C; Quantin C; Le Teuff G; Pagliano JF; Abrahamowicz M; Moreau T Neuroepidemiology; 2006; 27(1):45-54. PubMed ID: 16825794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]